NEW YORK, May 02, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the treatment of cancers, today announced that Lawrence S. Lamb, Ph.D., scientific co-founder and Chief Scientific Officer of Incysus will present at a scientific symposium on Thursday, May 9, 2019 during the Allogenic Cell Therapies Summit 2019 (ACTS), in Boston, Massachusetts.

Session Title:“Driving the Road to Off-the-Shelf Allogenic γδ Cell Therapies”
Date and Time:Thursday, May 9, 2019, 9:00 a.m. Eastern Time
Speaker:Lawrence S. Lamb, Ph.D.
Synopsis:Incysus Therapeutics current clinical trials of allogeneic haploidentical γδ cell therapy for leukemia in the setting of hematopoietic cell transplant and the autologous Drug Resistant Immunotherapy of glioblastoma multiforme as a combination that will provide a platform to evaluate allogeneic and off-the-shelf T cell therapies for consolidation of therapy-resistant malignancies.

About the Allogenic Cell Therapies Summit (ACTS)

The Allogeneic Cell Therapy Summit is focused on the clinical and commercial development of engineered allogeneic cell therapies with improved manufacturing and commercialization to benefit patients in need. The meeting brings together leading experts driving towards the future of cell therapies with allogeneic cell therapy approaches that are enhanced through engineering boasting a simpler and more cost- effective manufacturing strategies with improved commercial benefits.

About Incysus Therapeutics, Inc.
Incysus is focused on delivering a novel off-the-shelf cell therapy for the treatment of cancer. By using genetically modified gamma-delta (γδ) T cells, the Company’s technology addresses the challenges that immunotherapies face targeting cold, low mutation cancers. Incysus’ immuno-oncology programs include activated and gene- modified adoptive cellular therapies that protect cells from chemotherapy and allow novel combinations to disrupt the tumor microenvironment and more selectively target cancer cells. Since the Company’s inception in early 2016, Incysus has received approval of two Investigational New Drug applications (IND) and has initiated several cancer programs in early pre-clinical stages, including a checkpoint combination program. The Company’s first program is targeted to leukemia and lymphoma patients and its second program is targeted to the treatment of patients with newly-diagnosed glioblastoma (GBM). In collaboration with our academic partners, including the University of Alabama at Birmingham (UAB), Incysus has advanced its technology and expects to begin both Phase 1 trials during 2019. For more information, visit

Forward Looking Statements.
Certain statements herein concerning the Company’s future expectations, plans and prospects, including without limitation, the Company’s current expectations regarding its business strategy, product candidates, and clinical development process and timing, constitute forward-looking statements. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” the negative of these and other similar expressions are intended to identify such forward looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond the Company’s control. Consequently, actual future results may differ materially from the anticipated results expressed in such statements. In the case of forward-looking statements regarding investigational product candidates and continuing further development efforts, specific risks which could cause actual results to differ materially from the Company’s current expectations include: scientific, regulatory and technical developments; failure to demonstrate safety, tolerability and efficacy; final and quality controlled verification of data and the related analyses; expense and uncertainty of obtaining regulatory approval, including from the U.S. Food and Drug Administration; and the Company’s reliance on third parties, including licensors and clinical research organizations. Do not place undue reliance on any forward-looking statements included herein, which speak only as of the date hereof and which the Company is under no obligation to update or revise as a result of any event, circumstances or otherwise, unless required by applicable law.

Incysus Therapeutics, Inc.
+1 646.600.6GDT